The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Phase:
PHASE3
Details
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborators:
Affiliated Hospital of Guangdong Medical University Dongguan People's Hospital First Affiliated Hospital of Gannan Medical University First Affiliated Hospital of Guangxi Medical University First People's Hospital of Chenzhou First People's Hospital of Foshan Ganzhou City People's Hospital Guangdong Provincial Hospital of Traditional Chinese Medicine Guangdong Second Provincial General Hospital Guangzhou First People's Hospital Huizhou Municipal Central Hospital Hunan Provincial People's Hospital Jiangmen Central Hospital People's Hospital of Guangxi Zhuang Autonomous Region Shenzhen Hospital of Southern Medical University Shenzhen Second People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University